Home › Funds › D. E. Shaw & Co › ROIV
D. E. Shaw & Co position in ROIV
ROIVANT SCIENCES LTD · Health Care
Latest position (Q2 2026)2.97M sh
Reported value held$105.20M
Portfolio Weight0.05%
First reportedQ4 2022
Last changeAdd
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2022 | 125.53K | $1.00M | New |
| Q2 2025 | 83.68K | $943.12K | New |
| Q3 2025 | 548.06K | $8.29M | Add |
| Q4 2025 | 395.40K | $8.58M | Reduce |
| Q1 2026 | 1.39M | $38.58M | Add |
| Q2 2026 | 2.97M | $105.20M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
Other funds holding ROIV
- Fidelity Management & Research (FMR) 81.02M sh · $2.87B · Q2 2026
- BlackRock Inc 48.24M sh · $1.71B · Q2 2026
- Morgan Stanley 42.59M sh · $1.51B · Q2 2026
- Vanguard Group 42.06M sh · $912.68M · Q4 2025
- Goldman Sachs Group 18.56M sh · $656.71M · Q2 2026
- UBS Group AG 17.47M sh · $618.14M · Q2 2026
- Farallon Capital Management 14.31M sh · $506.40M · Q2 2026
- Geode Capital Management 11.67M sh · $425.54M · Q2 2026
- Wells Fargo & Co 9.72M sh · $344.04M · Q2 2026
- Invesco Ltd 7.53M sh · $266.53M · Q2 2026
- AQR Capital Management 6.63M sh · $234.03M · Q2 2026
- Viking Global Investors 6.27M sh · $221.95M · Q2 2026